Cite
HARVARD Citation
Delaloge, S. et al. (2019). Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Annals of oncology. pp. 567-574. [Online].